Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bimatoprost grenod - NicOx

Next Previous
Drug Profile

Bimatoprost grenod - NicOx

Alternative Names: Bimatoprost-NO; NCX-470; nitric oxide (NO)-donating bimatoprost prostaglandin analog; NO-bimatoprost; OT-301

Latest Information Update: 05 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NicOx
  • Developer NicOx; Ocumension Therapeutics
  • Class Amides; Antiglaucomas; Benzene derivatives; Cycloparaffins; Esters; Lipids; Nitro compounds; Prostaglandins; Small molecules
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Ocular hypertension; Open-angle glaucoma

Most Recent Events

  • 28 May 2025 Kowa received clinical trial approval for the initiation of a phase III trial in Japan
  • 27 May 2025 Nicox plans two phase IIIb trial for Ocular hypertension in second half of 2025 in Japan (Ophthalmic)
  • 17 Mar 2025 Nicox Ophthalmics completes the phase II/III Whistler trial in Open-angle glaucoma (In volunteers) in the USA (Ophthalmic) (NCT05938699)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top